Exclusion criteria | Number (%) of trials (n= 96) | Vasopressors (n= 37) | Fluid loading (n= 8) | Steroids (n= 8) | Modulation of immunity (n= 28) | Modulation of coagulation (n= 11) | Miscellaneous (n= 4) |
---|---|---|---|---|---|---|---|
Pregnancy | 46 (47%) | 16 (43%) | 2 (25%) | 4 (50%) | 15 (54%) | 6 (55%) | 4 (100%) |
Age <18 years | 39 (40%) | 7 (19%) | 6 (75%) | 5 (63%) | 13 (46%) | 7 (63%) | 1 (25%) |
Age >75 years | 4 (4%) | 1 (3%) | 1 (13%) | 1 (13%) | 1 (4%) | 0 | 0 |
Congestive heart failure | 34 (35%) | 13 (35%) | 2 (25%) | 3 (38%) | 12 (43%) | 2 (18%) | 1 (25%) |
Cancer | 29 (30%) | 7 (19%) | 2 (25%) | 3 (38%) | 11 (39%) | 6 (55%) | 2 (50%) |
Gastrointestinal and liver disorder | 17 (18%) | 6 (16%) | 2 (25%) | 2 (25%) | 6 (21%) | 3 (27%) | 1 (25%) |
Use of steroids | 16 (16%) | 0 | 0 | 7 (88%) | 11 (39%) | 0 | 0 |
HIV infection | 15 (15%) | 0 | 1 (13%) | 3 (%) | 9 (32%) | 1 (9%) | 0 |
Solid organ graft | 14 (14%) | 0 | 1 (13%) | 4 (50%) | 7 (25%) | 2 (18%) | 0 |
Coagulation abnormalities | 12 (12%) | 0 | 1 (13%) | 2 (25%) | 5 (18%) | 6 (55%) | 0 |
Burns | 11 (11%) | 0 | 1 (13%) | 3 (38%) | 4 (14%) | 3 (27%) | 0 |
Renal replacement therapy | 11 (11%) | 3 (8%) | 1 (13%) | 1 (13%) | 3 (10%) | 3 (27%) | 0 |
Overweight | 7 (7%) | 0 | 0 | 0 | 2 (7%) | 4 (36%) | 0 |
Neutropenia | 5 (5%) | 1 (3%) | 0 | 0 | 4 (14%) | 0 | 0 |
Cerebrovascular stroke | 3 (3%) | 0 | 1 (13%) | 0 | 0 | 1 (9%) | 0 |